Latest market price
78.05
-4.86-5.86%
GMEDQT61Globus Medical, Inc.·NYSE
78.05-5.86%
News
Down 5.9% — SYK Stock Skids as Q3 Earnings and Sales Miss & 2026 Outlook Cut (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E20.06EPS (ttm)3.89Insider Own17.62%Shs Outstand134.26MPerf Week-4.13%
Market Cap10.48BForward P/E14.48EPS next Y5.39Insider Trans-0.34%Shs Float133.30MPerf Month4.89%
Enterprise Value9.98BPEG1.91EPS next Q1.20Short Float6.14%Perf Quarter-4.19%
Income536.00MP/S3.33EPS this Y29.76%Short Ratio5.73Perf Half Y-14.55%
Sales3.15BP/B2.20EPS next Y7.83%ROA9.76%Short Interest8.19MPerf YTD-10.61%
Book/sh35.52P/C17.61EPS next 5Y10.52%ROE11.59%52W High101.40 -23.03%Perf Year26.95%
Cash/sh4.43P/FCF13.95EPS past 3/5Y28.44% 31.16%ROIC10.46%52W Low59.51 31.15%Perf 3Y67.27%
Dividend Est.—EV/EBITDA10.56Sales past 3/5Y42.16% 30.08%Gross Margin68.55%Volatility2.31% 2.71%Perf 5Y-2.34%
Dividend TTM—EV/Sales3.17EPS Y/Y TTM49.62%Oper. Margin20.75%ATR (14)2.28Perf 10Y239.20%
Dividend Ex-Date—Quick Ratio2.93Sales Y/Y TTM19.76%Profit Margin17.03%RSI (14)49.03Recom2.31
Dividend Gr. 3/5Y—Current Ratio4.62EPS Q/Q55.81%SMA200.03%Beta0.97Target Price95.13
Payout0.00%Debt/Eq0.02Sales Q/Q6.04%SMA500.56%Rel Volume1.18Prev Close82.91
Employees6,000LT Debt/Eq0.02EarningsNov 05SMA200-6.52%Avg Volume1.42MPrice78.05
IPO DateAug 03, 2012Option/ShortYes / YesEPS/Sales Surpr.21.91% 0.86%Net Debt/EBITDA-0.53Volume1,675,216Change-5.86%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-01-26ReiteratedRBC CapitalOutperform$115 → $85
Jul-28-26InitiatedUBSNeutral$82
Jul-16-26ReiteratedTruist SecuritiesBuy$115 → $100
Jul-13-26ReiteratedRBC CapitalOutperform$100 → $115
Jul-08-26InitiatedBMO CapitalOutperform$94
Jul-08-26ReiteratedStifel Nicolaus$64 → $80
Jun-15-26ReiteratedPiper SandlerOverweight$115 → $100
May-08-26ReiteratedNeedhamBuy$112 → $117
May-08-26ReiteratedWells FargoOverweight$78 → $103
Feb-25-26ReiteratedTruist FinancialBuy$105 → $115
Latest News· Times ET
Oct-30-26
Oct-29-26
Oct-27-26
Oct-23-26
Oct-21-26
Oct-16-26
Oct-14-26
Oct-13-26
Oct-12-26
Oct-07-26
Oct-06-26
Oct-05-26
Company

Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,1452,9392,5191,568—————
Cost of Goods Sold Incl. D&A9889581,035548—————
Gross Profit2,1561,9811,4841,020—————
Selling, General and Administrative Excl. Other1,3551,316981643—————
Research and Development185185164124—————
Other Operating Expense-350173120—————
Operating Income653480166133—————
Interest Expense0040—————
Unusual Expense
—————————
Non-Operating Income (Expense)12130-4132—————
Net Income Before Taxes665610121165—————
Income Taxes129721843—————
Consolidated Net Income536538103123—————
Net Income From Continuing Operations536538103123—————
Net Income536538103123—————
EPS (Recurring)3.973.980.761.09—————
EPS (Basic, Before Extraordinaries)3.973.980.761.09—————
EPS (Diluted)3.893.920.751.07—————
EBITDA945887474347—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio20.0622.27110.2849.80—————
Price To Sales Ratio3.354.014.473.84—————
Gross Margin68.5567.4058.9165.05—————
Operating Margin20.7616.336.598.48—————
Net Margin17.0418.314.097.84—————
Shares Outstanding135135136113—————
Market Capitalization10,53711,78711,2496,022—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$103.08$89.52$75.96$62.40$48.84● Close Price0.00M1.44M2.88M4.31M5.75MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
TOBIN JAMES RDirectorSep 15 '26Sale74.5830,0002,237,5020Sep 16
TOBIN JAMES RDirectorSep 15 '26Option Exercise58.7230,0001,761,45030,000Sep 16
ZARRILLI STEPHEN TDirectorAug 18 '26Option Exercise53.2725,0001,331,75025,000Aug 19
ZARRILLI STEPHEN TDirectorAug 18 '26Sale87.0425,0002,175,9650Aug 19
Davidar David DDirectorJun 05 '26Option Exercise26.2725,000656,750535,175Jun 09
Davidar David DDirectorJun 05 '26Sale80.7625,0002,019,073510,175Jun 09
RHOADS ANN DDirectorJun 04 '26Option Exercise26.2725,000656,75040,384Jun 08
Huller KellyEVP, GC, Corporate SecretaryFeb 25 '26Option Exercise43.5820,000871,60020,000Feb 27
Huller KellyEVP, GC, Corporate SecretaryFeb 25 '26Sale94.5020,0001,890,0000Feb 27
Huller KellyEVP, GC, Corporate SecretaryFeb 12 '26Option Exercise45.6410,000456,40010,000Feb 17
Huller KellyEVP, GC, Corporate SecretaryFeb 12 '26Sale87.6710,000876,7000Feb 17
Kline KyleSenior Vice President, CFOJan 08 '26Option Exercise51.873,594186,4213,594Jan 12
Kline KyleSenior Vice President, CFOJan 08 '26Sale101.103,594363,3530Jan 12
Norwalk Leslie VDirectorJan 08 '26Sale101.102,000202,20010,419Jan 12
Norwalk Leslie VDirectorDec 12 '25Sale88.854,000355,40012,419Dec 16
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.